A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi's sarcoma: protocol.
A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi's sarcoma: protocol.
复制标题
DOI：
10.1186/s43058-022-00281-7
复制
发表时间：
2022-05-13
影响因子：
--
通讯作者：
Freeman, Esther E.
中科院分区：
文献类型：
--
作者：
Collier, Sigrid;Semeere, Aggrey;Byakwaga, Helen;Laker-Oketta, Miriam;Chemtai, Linda;Wagner, Anjuli D.;Bassett, Ingrid V.;Wools-Kaloustian, Kara;Maurer, Toby;Martin, Jeffrey;Kiprono, Samson;Freeman, Esther E.
关键词：
对于晚期卡波西肉瘤（KS）患者，这是撒哈拉以南非洲地区常见的HIV相关恶性肿瘤，尽管抗逆转录病毒治疗和化疗越来越广泛，但KS诊断后2年内的死亡率估计为45%。对于晚期KS，除了抗逆转录病毒治疗外，化疗还可以改善预后并挽救生命，但目前，在肯尼亚西部有化疗指征的KS患者中，只有约50%的人实际接受了化疗。该方案描述了对多组分患者导航策略的评估，该策略解决了晚期KS患者中循证化疗服务渗透和保真度的常见障碍。肯尼亚的KS期。这是一项混合III型有效性-实施研究，采用非随机、前后设计嵌套在纵向队列中。我们将比较在推出多组分患者导航策略之前（2016-2020年）和之后（2021-2024年）期间晚期KS循证化疗的实施情况。多组分患者导航策略是在一个系统的过程中开发的，以解决肯尼亚西部化疗服务渗透和忠诚度的关键决定因素，包括（1）物理导航和护理协调，（2）基于视频的教育，（3）旅行津贴，（4）健康保险注册援助，（5）健康保险津贴，（6）同伴指导。我们将比较导航前阶段和导航后阶段，以评估这种多组分患者导航策略对（1）实施结局的影响：服务渗透（化疗开始）和忠诚度（化疗完成）和（2）服务和客户结局：癌症护理的及时性、死亡率、生活质量、耻辱和社会支持。我们还将描述多组分患者导航策略的实施过程和实施成功的决定因素。这项研究解决了一个迫切需要有效的实施策略，以提高在先进阶段KS循证化疗的开始和完成。通过使用明确规定的，基于理论的实施策略和验证的框架，本研究将有助于更全面地了解如何改善晚期KS的癌症治疗。在线版本包含补充材料，可通过10.1186/s43058-022-00281-7获得。
For people with advanced-stage Kaposi’s sarcoma (KS), a common HIV-associated malignancy in sub-Saharan Africa, mortality is estimated to be 45% within 2 years after KS diagnosis, despite increasingly wide-spread availability of antiretroviral therapy and chemotherapy. For advanced-stage KS, chemotherapy in addition to antiretroviral therapy improves outcomes and saves lives, but currently, only ~50% of people with KS in western Kenya who have an indication for chemotherapy actually receive it. This protocol describes the evaluation of a multicomponent patient navigation strategy that addresses common barriers to service penetration of and fidelity to evidence-based chemotherapy among people with advanced-stage KS in Kenya. This is a hybrid type III effectiveness-implementation study using a non-randomized, pre- post-design nested within a longitudinal cohort. We will compare the delivery of evidence-based chemotherapy for advanced-stage KS during the period before (2016–2020) to the period after (2021–2024), the rollout of a multicomponent patient navigation strategy. The multicomponent patient navigation strategy was developed in a systematic process to address key determinants of service penetration of and fidelity to chemotherapy in western Kenya and includes (1) physical navigation and care coordination, (2) video-based education, (3) travel stipend, (4) health insurance enrollment assistance, (5) health insurance stipend, and (6) peer mentorship. We will compare the pre-navigation period to the post-navigation period to assess the impact of this multicomponent patient navigation strategy on (1) implementation outcomes: service penetration (chemotherapy initiation) and fidelity (chemotherapy completion) and (2) service and client outcomes: timeliness of cancer care, mortality, quality of life, stigma, and social support. We will also describe the implementation process and the determinants of implementation success for the multicomponent patient navigation strategy. This study addresses an urgent need for effective implementation strategies to improve the initiation and completion of evidence-based chemotherapy in advanced-stage KS. By using a clearly specified, theory-based implementation strategy and validated frameworks, this study will contribute to a more comprehensive understanding of how to improve cancer treatment in advanced-stage KS. The online version contains supplementary material available at 10.1186/s43058-022-00281-7.
登录
查看更多内容
DOI：
10.1007/s00520-019-04833-x
发表时间：
2020-02
期刊：
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
影响因子：
--
作者：
Jean-Pierre P;Shao C;Cheng Y;Wells KJ;Paskett E;Fiscella K
通讯作者：
Fiscella K
影响因子：
3.4
作者：
Krown SE
通讯作者：
Krown SE
影响因子：
6.2
作者：
Jean-Pierre, Pascal;Fiscella, Kevin;Winters, Paul C.
通讯作者：
Winters, Paul C.
影响因子：
6
作者：
Matthews, Lynn T.;Orrell, Catherine;Haberer, Jessica E.
通讯作者：
Haberer, Jessica E.
DOI：
10.1097/qai.0b013e318251aedd
发表时间：
2012-06-01
期刊：
Journal of acquired immune deficiency syndromes (1999)
影响因子：
--
作者：
Mosam A;Shaik F;Uldrick TS;Esterhuizen T;Friedland GH;Scadden DT;Aboobaker J;Coovadia HM
通讯作者：
Coovadia HM